Marco Schmidt
Marco is a biochemist with a strong expertise in Chemical Biology & Drug Discovery. In his PhD thesis he developed novel methods for fragment-based drug discovery that was honored by the German Chemical Society with the Klaus Grohe Prize of Medicinal Chemistry. Afterwards he joined the University Chemical Laboratory Cambridge UK, working for the Bill & Melinda Gates Foundation on novel anti-tuberculosis drugs. During his stay at the University of Cambridge Marco was awarded with a Marie Curie Fellowship of the European Commission. After his return to Germany he co-founded biotx.ai, a company that developed an AI for the analysis …
Marco is a biochemist with a strong expertise in Chemical Biology & Drug Discovery. In his PhD thesis he developed novel methods for fragment-based drug discovery that was honored by the German Chemical Society with the Klaus Grohe Prize of Medicinal Chemistry. Afterwards he joined the University Chemical Laboratory Cambridge UK, working for the Bill & Melinda Gates Foundation on novel anti-tuberculosis drugs. During his stay at the University of Cambridge Marco was awarded with a Marie Curie Fellowship of the European Commission. After his return to Germany he co-founded biotx.ai, a company that developed an AI for the analysis of wide genomic data to overcome the missing heritability problem in genomics. biotx.ai has been recently named as a Deep Tech Pioneer by Hello Tomorrow.
See more
Articles: Marco Schmidt
Pharma’s Data Problem
Opinion / Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’. Data is the new oil, but biomedical data – despite its abundance – is closer to fracking…
Latest Report
